Study of DZD6008 for advanced NSCLC with EGFR mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Advanced lung cancer (NSCLC) that cannot be cured with standard treatments
- Must have a specific EGFR gene change (exon19 deletion or L858R mutation) found in your tumor
- For previously treated patients: must have progressed on or could not tolerate at least one prior EGFR inhibitor
- For treatment-naive patients: must not have received prior EGFR inhibitor therapy
- Good physical condition (ECOG 0 or 1) and expected life expectancy of at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a drug called sunvozertinib in people with advanced non-small cell lung cancer (NSCLC) that has not been treated yet. It is for those who have certain uncommon changes in the EGFR gene. The drug may shrink tumors or stop them from growing.
This trial tests a new combination therapy (DZD6008 plus other drugs) for people with advanced lung cancer that has an EGFR mutation and has stopped responding to a third-generation targeted therapy. It aims to find a better treatment option for these patients.
This study tests a new targeted therapy, sunvozertinib, for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to previous treatments. It may be an option if you have already tried chemotherapy and an EGFR-targeting drug.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.